Stem definition | Drug id | CAS RN |
---|---|---|
tyrosine kinase inhibitors | 1423 | 152459-95-5 |
Dose | Unit | Route |
---|---|---|
0.40 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 1 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 5 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 20.26 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 98 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 3.90 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 3.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.05 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 22 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 7, 2001 | EMA | Novartis Europharm Limited | |
May 10, 2001 | FDA | NOVARTIS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Death | 1594.24 | 12.50 | 1622 | 38268 | 355610 | 52953566 |
Gastrointestinal stromal tumour | 855.91 | 12.50 | 195 | 39695 | 1004 | 53308172 |
Chronic myeloid leukaemia | 832.33 | 12.50 | 224 | 39666 | 2490 | 53306686 |
Blast crisis in myelogenous leukaemia | 673.09 | 12.50 | 139 | 39751 | 403 | 53308773 |
Drug resistance | 553.75 | 12.50 | 279 | 39611 | 19683 | 53289493 |
Cytogenetic analysis abnormal | 543.91 | 12.50 | 124 | 39766 | 640 | 53308536 |
Malignant neoplasm progression | 431.74 | 12.50 | 386 | 39504 | 71155 | 53238021 |
Second primary malignancy | 424.20 | 12.50 | 170 | 39720 | 6962 | 53302214 |
Periorbital oedema | 313.68 | 12.50 | 126 | 39764 | 5189 | 53303987 |
Gene mutation identification test positive | 252.86 | 12.50 | 50 | 39840 | 107 | 53309069 |
Chronic myeloid leukaemia recurrent | 227.53 | 12.50 | 49 | 39841 | 184 | 53308992 |
Neoplasm malignant | 220.69 | 12.50 | 170 | 39720 | 25431 | 53283745 |
Philadelphia chromosome positive | 219.66 | 12.50 | 51 | 39839 | 289 | 53308887 |
Rheumatoid arthritis | 197.46 | 12.50 | 9 | 39881 | 314522 | 52994654 |
Muscle spasms | 187.29 | 12.50 | 350 | 39540 | 134445 | 53174731 |
Chromosome analysis abnormal | 183.75 | 12.50 | 38 | 39852 | 111 | 53309065 |
Pleural effusion | 180.42 | 12.50 | 273 | 39617 | 88306 | 53220870 |
Leukaemia recurrent | 174.85 | 12.50 | 58 | 39832 | 1369 | 53307807 |
Acute lymphocytic leukaemia recurrent | 167.03 | 12.50 | 63 | 39827 | 2185 | 53306991 |
Chronic myeloid leukaemia transformation | 166.37 | 12.50 | 35 | 39855 | 114 | 53309062 |
Oedema | 162.67 | 12.50 | 237 | 39653 | 74109 | 53235067 |
Eyelid oedema | 139.48 | 12.50 | 91 | 39799 | 10463 | 53298713 |
Gastric antral vascular ectasia | 138.16 | 12.50 | 40 | 39850 | 590 | 53308586 |
Eye swelling | 136.50 | 12.50 | 120 | 39770 | 21574 | 53287602 |
Bone marrow failure | 113.62 | 12.50 | 126 | 39764 | 29989 | 53279187 |
Fluid retention | 109.74 | 12.50 | 167 | 39723 | 54234 | 53254942 |
Nausea | 108.20 | 12.50 | 946 | 38944 | 755145 | 52554031 |
Pancytopenia | 103.11 | 12.50 | 217 | 39673 | 90711 | 53218465 |
Haematotoxicity | 99.27 | 12.50 | 66 | 39824 | 7831 | 53301345 |
Face oedema | 96.57 | 12.50 | 96 | 39794 | 20144 | 53289032 |
Conjunctival haemorrhage | 94.76 | 12.50 | 47 | 39843 | 3197 | 53305979 |
Graft versus host disease | 93.11 | 12.50 | 61 | 39829 | 7061 | 53302115 |
Drug hypersensitivity | 93.01 | 12.50 | 41 | 39849 | 265201 | 53043975 |
Product substitution issue | 92.35 | 12.50 | 84 | 39806 | 15782 | 53293394 |
Anaemia | 91.35 | 12.50 | 429 | 39461 | 276289 | 53032887 |
Oedema peripheral | 88.64 | 12.50 | 305 | 39585 | 170482 | 53138694 |
Arthropathy | 85.64 | 12.50 | 5 | 39885 | 141448 | 53167728 |
Normal newborn | 83.07 | 12.50 | 57 | 39833 | 7122 | 53302054 |
Gene mutation | 81.20 | 12.50 | 32 | 39858 | 1251 | 53307925 |
Pseudoporphyria | 80.50 | 12.50 | 20 | 39870 | 157 | 53309019 |
Completed suicide | 80.38 | 12.50 | 6 | 39884 | 138195 | 53170981 |
Blast cell crisis | 79.98 | 12.50 | 17 | 39873 | 59 | 53309117 |
Cytogenetic abnormality | 78.06 | 12.50 | 25 | 39865 | 526 | 53308650 |
Generalised oedema | 74.60 | 12.50 | 73 | 39817 | 15026 | 53294150 |
Thrombocytosis | 73.83 | 12.50 | 48 | 39842 | 5484 | 53303692 |
Recurrent cancer | 73.21 | 12.50 | 33 | 39857 | 1809 | 53307367 |
Metastases to liver | 72.70 | 12.50 | 85 | 39805 | 21411 | 53287765 |
Growth retardation | 70.54 | 12.50 | 28 | 39862 | 1116 | 53308060 |
Pain | 69.50 | 12.50 | 218 | 39672 | 588180 | 52720996 |
Swelling face | 68.96 | 12.50 | 140 | 39750 | 57028 | 53252148 |
Systemic lupus erythematosus | 68.70 | 12.50 | 7 | 39883 | 125407 | 53183769 |
Acute lymphocytic leukaemia | 67.74 | 12.50 | 36 | 39854 | 2829 | 53306347 |
Disease progression | 67.45 | 12.50 | 198 | 39692 | 101722 | 53207454 |
Exposure via father | 66.94 | 12.50 | 20 | 39870 | 331 | 53308845 |
Chronic graft versus host disease | 66.43 | 12.50 | 37 | 39853 | 3191 | 53305985 |
Thrombocytopenia | 65.29 | 12.50 | 240 | 39650 | 138487 | 53170689 |
Off label use | 64.55 | 12.50 | 163 | 39727 | 472049 | 52837127 |
Rash | 63.79 | 12.50 | 559 | 39331 | 445632 | 52863544 |
Pericardial effusion | 62.58 | 12.50 | 89 | 39801 | 27189 | 53281987 |
Splenomegaly | 62.18 | 12.50 | 56 | 39834 | 10383 | 53298793 |
Vomiting | 62.10 | 12.50 | 605 | 39285 | 496534 | 52812642 |
Hepatotoxicity | 61.08 | 12.50 | 89 | 39801 | 27791 | 53281385 |
Hypotension | 58.76 | 12.50 | 62 | 39828 | 254014 | 53055162 |
Neoplasm recurrence | 58.48 | 12.50 | 31 | 39859 | 2423 | 53306753 |
Therapeutic response decreased | 57.97 | 12.50 | 117 | 39773 | 47452 | 53261724 |
Therapeutic product effect decreased | 57.34 | 12.50 | 12 | 39878 | 125643 | 53183533 |
Bone pain | 56.23 | 12.50 | 120 | 39770 | 50602 | 53258574 |
Neoplasm progression | 54.95 | 12.50 | 88 | 39802 | 29831 | 53279345 |
Drug intolerance | 54.65 | 12.50 | 300 | 39590 | 205193 | 53103983 |
Leukaemia | 54.03 | 12.50 | 34 | 39856 | 3672 | 53305504 |
Diarrhoea | 52.71 | 12.50 | 705 | 39185 | 624841 | 52684335 |
Polymerase chain reaction positive | 51.98 | 12.50 | 12 | 39878 | 66 | 53309110 |
White blood cell count increased | 51.95 | 12.50 | 110 | 39780 | 46135 | 53263041 |
Eye haemorrhage | 49.07 | 12.50 | 43 | 39847 | 7691 | 53301485 |
Haemoglobin decreased | 48.99 | 12.50 | 218 | 39672 | 137089 | 53172087 |
Confusional state | 48.81 | 12.50 | 44 | 39846 | 194177 | 53114999 |
Fall | 48.70 | 12.50 | 124 | 39766 | 358316 | 52950860 |
Therapy non-responder | 48.56 | 12.50 | 111 | 39779 | 49009 | 53260167 |
Sinusitis | 47.60 | 12.50 | 34 | 39856 | 168530 | 53140646 |
Exposure via body fluid | 47.36 | 12.50 | 17 | 39873 | 511 | 53308665 |
Cardiac output decreased | 46.58 | 12.50 | 20 | 39870 | 975 | 53308201 |
Lower respiratory tract infection | 45.16 | 12.50 | 7 | 39883 | 90974 | 53218202 |
Glossodynia | 44.90 | 12.50 | 10 | 39880 | 100281 | 53208895 |
Metastases to peritoneum | 44.63 | 12.50 | 28 | 39862 | 3007 | 53306169 |
Platelet count increased | 44.53 | 12.50 | 57 | 39833 | 15750 | 53293426 |
Eye oedema | 44.43 | 12.50 | 22 | 39868 | 1491 | 53307685 |
Condition aggravated | 44.16 | 12.50 | 98 | 39792 | 297036 | 53012140 |
Chordoma | 43.40 | 12.50 | 7 | 39883 | 0 | 53309176 |
Neutropenia | 43.37 | 12.50 | 234 | 39656 | 158951 | 53150225 |
Myalgia | 43.22 | 12.50 | 206 | 39684 | 133285 | 53175891 |
Psoriasis | 42.55 | 12.50 | 7 | 39883 | 87082 | 53222094 |
Joint swelling | 41.27 | 12.50 | 70 | 39820 | 234568 | 53074608 |
Myelofibrosis | 41.26 | 12.50 | 20 | 39870 | 1294 | 53307882 |
Urinary tract infection | 40.00 | 12.50 | 74 | 39816 | 239829 | 53069347 |
Blast cells present | 39.81 | 12.50 | 14 | 39876 | 396 | 53308780 |
Product use issue | 39.60 | 12.50 | 28 | 39862 | 139556 | 53169620 |
Platelet count decreased | 39.58 | 12.50 | 173 | 39717 | 107926 | 53201250 |
Exposure via partner | 39.27 | 12.50 | 11 | 39879 | 143 | 53309033 |
Periorbital swelling | 39.14 | 12.50 | 21 | 39869 | 1682 | 53307494 |
Overdose | 38.75 | 12.50 | 16 | 39874 | 107720 | 53201456 |
Leukocytosis | 37.77 | 12.50 | 67 | 39823 | 24667 | 53284509 |
Wound | 37.39 | 12.50 | 11 | 39879 | 91546 | 53217630 |
Erythrocyanosis | 37.20 | 12.50 | 6 | 39884 | 0 | 53309176 |
Asthma | 36.35 | 12.50 | 18 | 39872 | 108954 | 53200222 |
Discomfort | 36.29 | 12.50 | 13 | 39877 | 95459 | 53213717 |
Jaundice | 36.26 | 12.50 | 74 | 39816 | 30239 | 53278937 |
Tumour excision | 36.05 | 12.50 | 13 | 39877 | 396 | 53308780 |
Blast cell count increased | 35.33 | 12.50 | 13 | 39877 | 420 | 53308756 |
Therapeutic response delayed | 35.03 | 12.50 | 14 | 39876 | 568 | 53308608 |
Chloroma | 34.96 | 12.50 | 11 | 39879 | 218 | 53308958 |
Peripheral arterial occlusive disease | 33.49 | 12.50 | 26 | 39864 | 3928 | 53305248 |
Skin fragility | 33.21 | 12.50 | 14 | 39876 | 652 | 53308524 |
Ascites | 33.05 | 12.50 | 84 | 39806 | 39651 | 53269525 |
Bone marrow oedema | 32.58 | 12.50 | 15 | 39875 | 864 | 53308312 |
Bone marrow transplant | 32.06 | 12.50 | 14 | 39876 | 711 | 53308465 |
Acute graft versus host disease | 31.48 | 12.50 | 26 | 39864 | 4291 | 53304885 |
Gastrointestinal toxicity | 31.27 | 12.50 | 27 | 39863 | 4735 | 53304441 |
White blood cell count decreased | 31.23 | 12.50 | 179 | 39711 | 124296 | 53184880 |
Pneumatosis intestinalis | 31.23 | 12.50 | 20 | 39870 | 2226 | 53306950 |
Pulse waveform abnormal | 31.23 | 12.50 | 8 | 39882 | 72 | 53309104 |
Loss of personal independence in daily activities | 31.16 | 12.50 | 7 | 39883 | 69808 | 53239368 |
Ankle brachial index decreased | 31.13 | 12.50 | 8 | 39882 | 73 | 53309103 |
Trisomy 8 | 31.00 | 12.50 | 5 | 39885 | 0 | 53309176 |
Blood lactate dehydrogenase increased | 30.71 | 12.50 | 57 | 39833 | 21724 | 53287452 |
Carotid intima-media thickness increased | 30.65 | 12.50 | 8 | 39882 | 78 | 53309098 |
Cardiotoxicity | 30.07 | 12.50 | 32 | 39858 | 7267 | 53301909 |
Nasopharyngitis | 29.71 | 12.50 | 62 | 39828 | 192233 | 53116943 |
Breast cancer | 28.98 | 12.50 | 92 | 39798 | 49266 | 53259910 |
Toxic skin eruption | 28.86 | 12.50 | 42 | 39848 | 13097 | 53296079 |
Right ventricular failure | 28.83 | 12.50 | 48 | 39842 | 16795 | 53292381 |
Musculoskeletal stiffness | 28.60 | 12.50 | 30 | 39860 | 123338 | 53185838 |
Typhoid fever | 28.19 | 12.50 | 6 | 39884 | 21 | 53309155 |
Surgery | 28.08 | 12.50 | 69 | 39821 | 31895 | 53277281 |
Intentional overdose | 27.57 | 12.50 | 8 | 39882 | 67197 | 53241979 |
Acute kidney injury | 27.14 | 12.50 | 98 | 39792 | 253770 | 53055406 |
Morphoea | 26.83 | 12.50 | 10 | 39880 | 335 | 53308841 |
Left ventricular dysfunction | 26.26 | 12.50 | 37 | 39853 | 11200 | 53297976 |
Aplasia | 25.98 | 12.50 | 23 | 39867 | 4169 | 53305007 |
Chronic graft versus host disease in skin | 25.92 | 12.50 | 12 | 39878 | 700 | 53308476 |
Anxiety | 25.18 | 12.50 | 70 | 39820 | 196634 | 53112542 |
Dizziness | 25.17 | 12.50 | 169 | 39721 | 372090 | 52937086 |
Tumour haemorrhage | 24.90 | 12.50 | 15 | 39875 | 1499 | 53307677 |
Pubertal failure | 24.89 | 12.50 | 5 | 39885 | 12 | 53309164 |
Slit-lamp tests abnormal | 24.80 | 12.50 | 4 | 39886 | 0 | 53309176 |
Peritoneal lesion | 24.80 | 12.50 | 4 | 39886 | 0 | 53309176 |
Hypersensitivity | 24.78 | 12.50 | 78 | 39812 | 210587 | 53098589 |
Tumour necrosis | 24.64 | 12.50 | 12 | 39878 | 784 | 53308392 |
Transdifferentiation of neoplasm | 24.60 | 12.50 | 5 | 39885 | 13 | 53309163 |
Blood pressure increased | 24.59 | 12.50 | 42 | 39848 | 140437 | 53168739 |
Cytopenia | 24.16 | 12.50 | 32 | 39858 | 9138 | 53300038 |
Urine odour abnormal | 24.07 | 12.50 | 25 | 39865 | 5521 | 53303655 |
Syncope | 24.03 | 12.50 | 29 | 39861 | 111964 | 53197212 |
Pyrexia | 24.02 | 12.50 | 429 | 39461 | 402764 | 52906412 |
Back pain | 24.00 | 12.50 | 92 | 39798 | 234155 | 53075021 |
Hepatic necrosis | 23.32 | 12.50 | 25 | 39865 | 5725 | 53303451 |
Abortion | 23.24 | 12.50 | 17 | 39873 | 2349 | 53306827 |
Abortion spontaneous | 23.02 | 12.50 | 82 | 39808 | 46553 | 53262623 |
Injury | 22.97 | 12.50 | 5 | 39885 | 50966 | 53258210 |
Hallucination | 22.85 | 12.50 | 6 | 39884 | 53832 | 53255344 |
Leukopenia | 22.77 | 12.50 | 112 | 39778 | 73351 | 53235825 |
Somnolence | 22.75 | 12.50 | 58 | 39832 | 167676 | 53141500 |
Intentional product use issue | 22.67 | 12.50 | 13 | 39877 | 72481 | 53236695 |
Inappropriate schedule of product administration | 22.61 | 12.50 | 14 | 39876 | 74864 | 53234312 |
Agitation | 22.24 | 12.50 | 8 | 39882 | 58618 | 53250558 |
Papilloedema | 22.13 | 12.50 | 20 | 39870 | 3723 | 53305453 |
Liver disorder | 21.90 | 12.50 | 73 | 39817 | 40082 | 53269094 |
Therapy partial responder | 21.89 | 12.50 | 25 | 39865 | 6138 | 53303038 |
Suicidal ideation | 21.73 | 12.50 | 9 | 39881 | 60502 | 53248674 |
Arthritis | 21.64 | 12.50 | 20 | 39870 | 87278 | 53221898 |
Insomnia | 21.48 | 12.50 | 70 | 39820 | 187002 | 53122174 |
Hyponatraemia | 21.37 | 12.50 | 30 | 39860 | 108577 | 53200599 |
Basophilia | 21.14 | 12.50 | 4 | 39886 | 6 | 53309170 |
Pericarditis | 20.93 | 12.50 | 11 | 39879 | 64395 | 53244781 |
Tremor | 20.74 | 12.50 | 39 | 39851 | 125697 | 53183479 |
Chylothorax | 20.51 | 12.50 | 8 | 39882 | 304 | 53308872 |
Intracardiac mass | 20.50 | 12.50 | 5 | 39885 | 36 | 53309140 |
Anaphylactic reaction | 20.42 | 12.50 | 9 | 39881 | 58317 | 53250859 |
Oral pigmentation | 20.41 | 12.50 | 4 | 39886 | 8 | 53309168 |
Therapy interrupted | 20.41 | 12.50 | 45 | 39845 | 19391 | 53289785 |
Hypertension | 20.33 | 12.50 | 93 | 39797 | 225338 | 53083838 |
Gastric cancer | 20.25 | 12.50 | 18 | 39872 | 3279 | 53305897 |
Flushing | 20.23 | 12.50 | 14 | 39876 | 70586 | 53238590 |
Drug ineffective | 20.16 | 12.50 | 462 | 39428 | 816783 | 52492393 |
Microangiopathy | 19.92 | 12.50 | 11 | 39879 | 933 | 53308243 |
Blood test abnormal | 19.83 | 12.50 | 33 | 39857 | 11544 | 53297632 |
Stem cell transplant | 19.82 | 12.50 | 14 | 39876 | 1831 | 53307345 |
Computerised tomogram abnormal | 19.65 | 12.50 | 15 | 39875 | 2211 | 53306965 |
Exposure during pregnancy | 19.61 | 12.50 | 160 | 39730 | 124700 | 53184476 |
Neoplasm | 19.50 | 12.50 | 24 | 39866 | 6372 | 53302804 |
Lacrimation increased | 19.42 | 12.50 | 42 | 39848 | 17861 | 53291315 |
Urticaria | 19.19 | 12.50 | 46 | 39844 | 135839 | 53173337 |
Obliterative bronchiolitis | 19.13 | 12.50 | 14 | 39876 | 1936 | 53307240 |
Exophthalmos | 18.83 | 12.50 | 12 | 39878 | 1324 | 53307852 |
Acute myeloid leukaemia | 18.69 | 12.50 | 40 | 39850 | 16892 | 53292284 |
Aspiration pleural cavity | 18.56 | 12.50 | 10 | 39880 | 808 | 53308368 |
Fibromyalgia | 18.54 | 12.50 | 5 | 39885 | 44070 | 53265106 |
Product dose omission issue | 18.52 | 12.50 | 77 | 39813 | 191543 | 53117633 |
Jaw operation | 18.50 | 12.50 | 10 | 39880 | 813 | 53308363 |
Myelocytosis | 18.37 | 12.50 | 4 | 39886 | 16 | 53309160 |
Mobility decreased | 18.29 | 12.50 | 18 | 39872 | 76253 | 53232923 |
Cellulitis | 18.15 | 12.50 | 18 | 39872 | 75971 | 53233205 |
Gastrointestinal angiectasia | 17.85 | 12.50 | 5 | 39885 | 65 | 53309111 |
Disseminated intravascular coagulation | 17.78 | 12.50 | 43 | 39847 | 19676 | 53289500 |
Eosinophilia | 17.63 | 12.50 | 45 | 39845 | 21290 | 53287886 |
Dengue fever | 17.59 | 12.50 | 9 | 39881 | 654 | 53308522 |
Influenza like illness | 17.52 | 12.50 | 12 | 39878 | 60847 | 53248329 |
Loss of consciousness | 17.48 | 12.50 | 37 | 39853 | 114175 | 53195001 |
Scleroderma-like reaction | 17.19 | 12.50 | 5 | 39885 | 75 | 53309101 |
Therapy cessation | 17.15 | 12.50 | 53 | 39837 | 27972 | 53281204 |
Pigmentation disorder | 17.05 | 12.50 | 18 | 39872 | 4049 | 53305127 |
Headache | 16.96 | 12.50 | 291 | 39599 | 536530 | 52772646 |
Hyperhidrosis | 16.88 | 12.50 | 29 | 39861 | 96764 | 53212412 |
Hepatic failure | 16.85 | 12.50 | 62 | 39828 | 35744 | 53273432 |
Hyperkalaemia | 16.58 | 12.50 | 10 | 39880 | 54246 | 53254930 |
Ejection fraction decreased | 16.54 | 12.50 | 42 | 39848 | 19806 | 53289370 |
Metastasis | 16.48 | 12.50 | 19 | 39871 | 4712 | 53304464 |
Fibrin degradation products increased | 16.45 | 12.50 | 6 | 39884 | 189 | 53308987 |
Acquired gene mutation | 16.24 | 12.50 | 9 | 39881 | 768 | 53308408 |
Deep vein thrombosis | 16.21 | 12.50 | 23 | 39867 | 82890 | 53226286 |
Lichen planus | 16.19 | 12.50 | 13 | 39877 | 2061 | 53307115 |
Abortion induced | 16.11 | 12.50 | 29 | 39861 | 10797 | 53298379 |
Swelling of eyelid | 15.96 | 12.50 | 12 | 39878 | 1728 | 53307448 |
Dry skin | 15.80 | 12.50 | 72 | 39818 | 45688 | 53263488 |
Blood blister | 15.78 | 12.50 | 12 | 39878 | 1759 | 53307417 |
Knee arthroplasty | 15.73 | 12.50 | 3 | 39887 | 33566 | 53275610 |
Tumour lysis syndrome | 15.62 | 12.50 | 24 | 39866 | 7850 | 53301326 |
Aspartate aminotransferase increased | 15.60 | 12.50 | 112 | 39778 | 83917 | 53225259 |
Philadelphia positive chronic myeloid leukaemia | 15.52 | 12.50 | 4 | 39886 | 37 | 53309139 |
Central nervous system leukaemia | 15.49 | 12.50 | 5 | 39885 | 108 | 53309068 |
Helicobacter infection | 15.39 | 12.50 | 5 | 39885 | 39064 | 53270112 |
Lichenoid keratosis | 15.21 | 12.50 | 11 | 39879 | 1494 | 53307682 |
Acute leukaemia | 15.19 | 12.50 | 10 | 39880 | 1166 | 53308010 |
Pulmonary embolism | 15.18 | 12.50 | 40 | 39850 | 114402 | 53194774 |
Acute myeloid leukaemia recurrent | 15.15 | 12.50 | 11 | 39879 | 1502 | 53307674 |
Delirium | 15.14 | 12.50 | 6 | 39884 | 41423 | 53267753 |
Hepatic mass | 15.10 | 12.50 | 11 | 39879 | 1510 | 53307666 |
Ocular hyperaemia | 15.03 | 12.50 | 43 | 39847 | 21748 | 53287428 |
Subdural haematoma evacuation | 14.99 | 12.50 | 3 | 39887 | 7 | 53309169 |
Food interaction | 14.86 | 12.50 | 8 | 39882 | 645 | 53308531 |
Type 2 diabetes mellitus | 14.49 | 12.50 | 3 | 39887 | 31667 | 53277509 |
Impaired healing | 14.44 | 12.50 | 16 | 39874 | 64189 | 53244987 |
Osteoarthritis | 14.33 | 12.50 | 19 | 39871 | 70467 | 53238709 |
Irritability | 14.02 | 12.50 | 3 | 39887 | 30950 | 53278226 |
Cystitis | 13.89 | 12.50 | 9 | 39881 | 46979 | 53262197 |
Myeloid maturation arrest | 13.78 | 12.50 | 3 | 39887 | 12 | 53309164 |
Dermatofibrosarcoma protuberans | 13.78 | 12.50 | 3 | 39887 | 12 | 53309164 |
Blood bilirubin increased | 13.69 | 12.50 | 58 | 39832 | 35672 | 53273504 |
Suicide attempt | 13.63 | 12.50 | 14 | 39876 | 58154 | 53251022 |
Oncologic complication | 13.58 | 12.50 | 5 | 39885 | 162 | 53309014 |
Primary adrenal insufficiency | 13.57 | 12.50 | 4 | 39886 | 63 | 53309113 |
Cardiac failure | 13.47 | 12.50 | 110 | 39780 | 85734 | 53223442 |
Adenocarcinoma gastric | 13.46 | 12.50 | 7 | 39883 | 526 | 53308650 |
Growth failure | 13.39 | 12.50 | 6 | 39884 | 324 | 53308852 |
Polyhydramnios | 13.38 | 12.50 | 12 | 39878 | 2213 | 53306963 |
Bone metabolism disorder | 13.34 | 12.50 | 6 | 39884 | 327 | 53308849 |
Gastrectomy | 13.28 | 12.50 | 7 | 39883 | 541 | 53308635 |
Hepatic enzyme increased | 13.28 | 12.50 | 49 | 39841 | 126146 | 53183030 |
Desmoid tumour | 13.18 | 12.50 | 4 | 39886 | 70 | 53309106 |
Hepatomegaly | 13.11 | 12.50 | 28 | 39862 | 11803 | 53297373 |
Leukaemic infiltration extramedullary | 13.07 | 12.50 | 4 | 39886 | 72 | 53309104 |
Therapeutic product effect incomplete | 13.01 | 12.50 | 31 | 39859 | 91753 | 53217423 |
Therapy responder | 13.01 | 12.50 | 6 | 39884 | 347 | 53308829 |
Hepatic neoplasm | 12.92 | 12.50 | 11 | 39879 | 1893 | 53307283 |
Drug level increased | 12.85 | 12.50 | 39 | 39851 | 20382 | 53288794 |
Complications of transplant surgery | 12.85 | 12.50 | 5 | 39885 | 189 | 53308987 |
Skin hypopigmentation | 12.83 | 12.50 | 7 | 39883 | 580 | 53308596 |
Skull fractured base | 12.82 | 12.50 | 4 | 39886 | 77 | 53309099 |
Red blood cell count decreased | 12.78 | 12.50 | 57 | 39833 | 35846 | 53273330 |
Central nervous system neoplasm | 12.77 | 12.50 | 3 | 39887 | 18 | 53309158 |
Blood alkaline phosphatase increased | 12.77 | 12.50 | 63 | 39827 | 41299 | 53267877 |
Arthralgia | 12.73 | 12.50 | 242 | 39648 | 439541 | 52869635 |
Balance disorder | 12.70 | 12.50 | 22 | 39868 | 73185 | 53235991 |
Blood creatine phosphokinase increased | 12.66 | 12.50 | 49 | 39841 | 28936 | 53280240 |
Myelodysplastic syndrome | 12.60 | 12.50 | 34 | 39856 | 16626 | 53292550 |
Therapy change | 12.56 | 12.50 | 18 | 39872 | 5534 | 53303642 |
Vaccination failure | 12.53 | 12.50 | 5 | 39885 | 202 | 53308974 |
Seizure | 12.53 | 12.50 | 52 | 39838 | 129457 | 53179719 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Death | 2388.69 | 12.34 | 2694 | 40045 | 379823 | 32090964 |
Gastrointestinal stromal tumour | 1153.30 | 12.34 | 281 | 42458 | 1029 | 32469758 |
Chronic myeloid leukaemia | 1066.48 | 12.34 | 309 | 42430 | 2475 | 32468312 |
Drug resistance | 825.31 | 12.34 | 460 | 42279 | 22505 | 32448282 |
Blast crisis in myelogenous leukaemia | 729.57 | 12.34 | 167 | 42572 | 429 | 32470358 |
Second primary malignancy | 607.41 | 12.34 | 256 | 42483 | 6685 | 32464102 |
Malignant neoplasm progression | 491.14 | 12.34 | 559 | 42180 | 77937 | 32392850 |
Cytogenetic analysis abnormal | 442.18 | 12.34 | 109 | 42630 | 423 | 32470364 |
Neoplasm malignant | 376.18 | 12.34 | 260 | 42479 | 18625 | 32452162 |
Philadelphia chromosome positive | 297.86 | 12.34 | 72 | 42667 | 252 | 32470535 |
Pleural effusion | 224.28 | 12.34 | 385 | 42354 | 78607 | 32392180 |
Drug intolerance | 211.71 | 12.34 | 294 | 42445 | 49941 | 32420846 |
Gene mutation | 198.68 | 12.34 | 67 | 42672 | 919 | 32469868 |
Chromosome analysis abnormal | 197.97 | 12.34 | 43 | 42696 | 78 | 32470709 |
Acute lymphocytic leukaemia recurrent | 193.49 | 12.34 | 90 | 42649 | 2982 | 32467805 |
Periorbital oedema | 157.82 | 12.34 | 82 | 42657 | 3466 | 32467321 |
Leukaemia recurrent | 155.25 | 12.34 | 64 | 42675 | 1575 | 32469212 |
Chronic myeloid leukaemia transformation | 154.22 | 12.34 | 38 | 42701 | 147 | 32470640 |
Metastases to liver | 151.62 | 12.34 | 130 | 42609 | 12802 | 32457985 |
Chronic myeloid leukaemia recurrent | 149.58 | 12.34 | 37 | 42702 | 146 | 32470641 |
Gene mutation identification test positive | 130.76 | 12.34 | 34 | 42705 | 171 | 32470616 |
Therapeutic response decreased | 114.06 | 12.34 | 155 | 42584 | 25765 | 32445022 |
Recurrent cancer | 105.83 | 12.34 | 45 | 42694 | 1199 | 32469588 |
Oedema | 105.01 | 12.34 | 202 | 42537 | 44945 | 32425842 |
Chronic graft versus host disease | 102.40 | 12.34 | 67 | 42672 | 4373 | 32466414 |
White blood cell count increased | 98.45 | 12.34 | 187 | 42552 | 41215 | 32429572 |
Blast cell crisis | 98.08 | 12.34 | 23 | 42716 | 68 | 32470719 |
Eyelid oedema | 96.35 | 12.34 | 69 | 42670 | 5220 | 32465567 |
Hypotension | 93.40 | 12.34 | 88 | 42651 | 216022 | 32254765 |
Muscle spasms | 91.24 | 12.34 | 250 | 42489 | 70168 | 32400619 |
Drug abuse | 88.51 | 12.34 | 4 | 42735 | 80239 | 32390548 |
Acute lymphocytic leukaemia | 88.32 | 12.34 | 56 | 42683 | 3462 | 32467325 |
Neoplasm recurrence | 87.30 | 12.34 | 46 | 42693 | 2001 | 32468786 |
Completed suicide | 81.96 | 12.34 | 12 | 42727 | 92505 | 32378282 |
Neoplasm progression | 81.14 | 12.34 | 114 | 42625 | 19544 | 32451243 |
Blast cells present | 79.21 | 12.34 | 29 | 42710 | 513 | 32470274 |
Acute kidney injury | 77.84 | 12.34 | 169 | 42570 | 293299 | 32177488 |
Overdose | 77.82 | 12.34 | 11 | 42728 | 87066 | 32383721 |
Polymerase chain reaction positive | 76.69 | 12.34 | 20 | 42719 | 102 | 32470685 |
Gastric antral vascular ectasia | 76.42 | 12.34 | 25 | 42714 | 310 | 32470477 |
Therapy non-responder | 74.56 | 12.34 | 145 | 42594 | 32509 | 32438278 |
Desmoid tumour | 74.18 | 12.34 | 19 | 42720 | 89 | 32470698 |
Splenomegaly | 68.93 | 12.34 | 90 | 42649 | 14387 | 32456400 |
Chordoma | 67.63 | 12.34 | 12 | 42727 | 0 | 32470787 |
Necrotising panniculitis | 67.45 | 12.34 | 15 | 42724 | 32 | 32470755 |
Face oedema | 66.93 | 12.34 | 80 | 42659 | 11695 | 32459092 |
Graft versus host disease | 62.38 | 12.34 | 74 | 42665 | 10732 | 32460055 |
Clonal evolution | 61.12 | 12.34 | 17 | 42722 | 115 | 32470672 |
Scleroderma | 60.81 | 12.34 | 32 | 42707 | 1388 | 32469399 |
Fluid retention | 59.51 | 12.34 | 117 | 42622 | 26433 | 32444354 |
Acquired gene mutation | 58.86 | 12.34 | 30 | 42709 | 1217 | 32469570 |
Fall | 58.82 | 12.34 | 105 | 42634 | 196096 | 32274691 |
Product substitution issue | 57.84 | 12.34 | 70 | 42669 | 10366 | 32460421 |
Blast cell count increased | 56.55 | 12.34 | 28 | 42711 | 1067 | 32469720 |
Metastases to peritoneum | 56.02 | 12.34 | 32 | 42707 | 1634 | 32469153 |
Prostate cancer | 55.75 | 12.34 | 116 | 42623 | 27290 | 32443497 |
Bradycardia | 55.42 | 12.34 | 13 | 42726 | 71549 | 32399238 |
Central nervous system leukaemia | 51.17 | 12.34 | 18 | 42721 | 282 | 32470505 |
Confusional state | 51.10 | 12.34 | 68 | 42671 | 143047 | 32327740 |
Off label use | 50.68 | 12.34 | 219 | 42520 | 306101 | 32164686 |
Cytogenetic abnormality | 50.15 | 12.34 | 24 | 42715 | 848 | 32469939 |
Disease progression | 48.98 | 12.34 | 235 | 42504 | 86627 | 32384160 |
Myelofibrosis | 47.94 | 12.34 | 29 | 42710 | 1648 | 32469139 |
Bone pain | 47.23 | 12.34 | 91 | 42648 | 20253 | 32450534 |
Treatment failure | 46.71 | 12.34 | 135 | 42604 | 39028 | 32431759 |
Accident | 45.40 | 12.34 | 40 | 42699 | 4082 | 32466705 |
Bone marrow necrosis | 45.07 | 12.34 | 14 | 42725 | 145 | 32470642 |
Hyperkalaemia | 44.45 | 12.34 | 18 | 42721 | 69732 | 32401055 |
Central nervous system neoplasm | 44.09 | 12.34 | 12 | 42727 | 74 | 32470713 |
Endocarditis noninfective | 43.99 | 12.34 | 13 | 42726 | 112 | 32470675 |
Pituitary apoplexy | 43.31 | 12.34 | 10 | 42729 | 27 | 32470760 |
Exposure via father | 42.72 | 12.34 | 13 | 42726 | 125 | 32470662 |
Haemoglobin decreased | 42.47 | 12.34 | 286 | 42453 | 119385 | 32351402 |
Bone marrow failure | 42.41 | 12.34 | 111 | 42628 | 30293 | 32440494 |
Typhoid fever | 42.29 | 12.34 | 10 | 42729 | 31 | 32470756 |
Chronic graft versus host disease in skin | 42.11 | 12.34 | 21 | 42718 | 813 | 32469974 |
Thrombocytopenia | 41.55 | 12.34 | 335 | 42404 | 147964 | 32322823 |
Somnolence | 40.52 | 12.34 | 46 | 42693 | 103751 | 32367036 |
Intentional overdose | 40.25 | 12.34 | 4 | 42735 | 41597 | 32429190 |
Pulmonary embolism | 39.79 | 12.34 | 31 | 42708 | 83628 | 32387159 |
Tumour haemorrhage | 39.23 | 12.34 | 31 | 42708 | 2720 | 32468067 |
Surgery | 39.10 | 12.34 | 64 | 42675 | 12535 | 32458252 |
Platelet count decreased | 38.37 | 12.34 | 270 | 42469 | 114321 | 32356466 |
Ascites | 38.17 | 12.34 | 128 | 42611 | 40063 | 32430724 |
Hallucination | 37.98 | 12.34 | 11 | 42728 | 52608 | 32418179 |
Tumour rupture | 36.65 | 12.34 | 13 | 42726 | 209 | 32470578 |
Toxicity to various agents | 36.08 | 12.34 | 117 | 42622 | 177924 | 32292863 |
Loss of therapeutic response | 35.09 | 12.34 | 13 | 42726 | 238 | 32470549 |
Tumour necrosis | 34.53 | 12.34 | 21 | 42718 | 1205 | 32469582 |
Colon cancer | 34.49 | 12.34 | 50 | 42689 | 8816 | 32461971 |
Generalised oedema | 34.22 | 12.34 | 60 | 42679 | 12423 | 32458364 |
Syncope | 34.03 | 12.34 | 41 | 42698 | 90083 | 32380704 |
Nausea | 33.28 | 12.34 | 599 | 42140 | 320250 | 32150537 |
Gastrectomy | 32.81 | 12.34 | 11 | 42728 | 148 | 32470639 |
Drug hypersensitivity | 32.68 | 12.34 | 29 | 42710 | 73371 | 32397416 |
Gastric cancer | 32.65 | 12.34 | 38 | 42701 | 5399 | 32465388 |
Seizure | 32.51 | 12.34 | 54 | 42685 | 103800 | 32366987 |
Pneumonia | 32.37 | 12.34 | 305 | 42434 | 354947 | 32115840 |
Delirium | 32.17 | 12.34 | 9 | 42730 | 44037 | 32426750 |
Cardiac arrest | 31.54 | 12.34 | 49 | 42690 | 96727 | 32374060 |
Pulmonary aplasia | 31.39 | 12.34 | 6 | 42733 | 3 | 32470784 |
Tuberculosis | 30.76 | 12.34 | 47 | 42692 | 8682 | 32462105 |
Rhabdomyolysis | 30.64 | 12.34 | 26 | 42713 | 67239 | 32403548 |
Inappropriate schedule of product administration | 30.56 | 12.34 | 11 | 42728 | 45814 | 32424973 |
Dizziness | 30.40 | 12.34 | 157 | 42582 | 209461 | 32261326 |
Eye swelling | 30.22 | 12.34 | 49 | 42690 | 9523 | 32461264 |
Growth retardation | 30.11 | 12.34 | 22 | 42717 | 1717 | 32469070 |
Pericardial effusion | 30.08 | 12.34 | 82 | 42657 | 22920 | 32447867 |
Pemphigus | 30.06 | 12.34 | 20 | 42719 | 1342 | 32469445 |
Deep vein thrombosis | 29.80 | 12.34 | 24 | 42715 | 63689 | 32407098 |
Tumour excision | 29.79 | 12.34 | 10 | 42729 | 135 | 32470652 |
Oral pigmentation | 29.66 | 12.34 | 6 | 42733 | 6 | 32470781 |
Psoriasis | 29.22 | 12.34 | 12 | 42727 | 46111 | 32424676 |
Chloroma | 29.14 | 12.34 | 14 | 42725 | 499 | 32470288 |
Anxiety | 29.06 | 12.34 | 51 | 42688 | 95954 | 32374833 |
Tremor | 28.59 | 12.34 | 39 | 42700 | 81238 | 32389549 |
Demyelination | 28.57 | 12.34 | 26 | 42713 | 2768 | 32468019 |
Loss of CAR T-cell persistence | 28.22 | 12.34 | 7 | 42732 | 28 | 32470759 |
Renal tuberculosis | 28.18 | 12.34 | 5 | 42734 | 0 | 32470787 |
Graft versus host disease in eye | 27.82 | 12.34 | 11 | 42728 | 242 | 32470545 |
Flushing | 27.63 | 12.34 | 4 | 42735 | 31123 | 32439664 |
Stem cell transplant | 27.34 | 12.34 | 23 | 42716 | 2204 | 32468583 |
Oedema peripheral | 27.33 | 12.34 | 249 | 42490 | 113842 | 32356945 |
Drug interaction | 27.02 | 12.34 | 172 | 42567 | 218013 | 32252774 |
Pseudoporphyria | 27.01 | 12.34 | 11 | 42728 | 262 | 32470525 |
Metabolic acidosis | 26.75 | 12.34 | 10 | 42729 | 40689 | 32430098 |
Drug clearance decreased | 26.42 | 12.34 | 19 | 42720 | 1446 | 32469341 |
Malaria | 26.41 | 12.34 | 11 | 42728 | 278 | 32470509 |
Hyperhidrosis | 26.21 | 12.34 | 33 | 42706 | 71135 | 32399652 |
Blindness | 26.03 | 12.34 | 55 | 42684 | 13071 | 32457716 |
Optic neuritis | 26.02 | 12.34 | 27 | 42712 | 3375 | 32467412 |
Blood lactate dehydrogenase increased | 25.83 | 12.34 | 75 | 42664 | 21730 | 32449057 |
Plasma cell myeloma | 25.36 | 12.34 | 23 | 42716 | 57591 | 32413196 |
Therapeutic product effect decreased | 25.29 | 12.34 | 5 | 42734 | 31012 | 32439775 |
Metamyelocyte count increased | 25.15 | 12.34 | 12 | 42727 | 421 | 32470366 |
Blood pressure increased | 25.07 | 12.34 | 41 | 42698 | 79313 | 32391474 |
International normalised ratio increased | 24.83 | 12.34 | 17 | 42722 | 49018 | 32421769 |
Haematotoxicity | 24.61 | 12.34 | 37 | 42702 | 6739 | 32464048 |
Chronic obstructive pulmonary disease | 24.55 | 12.34 | 17 | 42722 | 48736 | 32422051 |
Bone marrow disorder | 24.33 | 12.34 | 19 | 42720 | 1639 | 32469148 |
Rash | 23.87 | 12.34 | 397 | 42342 | 208936 | 32261851 |
Agitation | 23.85 | 12.34 | 24 | 42715 | 57212 | 32413575 |
Post embolisation syndrome | 23.22 | 12.34 | 7 | 42732 | 65 | 32470722 |
Bone marrow transplant | 22.80 | 12.34 | 15 | 42724 | 988 | 32469799 |
Bone neoplasm | 22.76 | 12.34 | 10 | 42729 | 289 | 32470498 |
Right ventricular diastolic collapse | 22.76 | 12.34 | 7 | 42732 | 70 | 32470717 |
Cardio-respiratory arrest | 22.73 | 12.34 | 24 | 42715 | 55965 | 32414822 |
Epistaxis | 22.61 | 12.34 | 24 | 42715 | 55831 | 32414956 |
Dehydration | 22.61 | 12.34 | 90 | 42649 | 128868 | 32341919 |
Spleen palpable | 22.54 | 12.34 | 4 | 42735 | 0 | 32470787 |
Acute aortic syndrome | 22.54 | 12.34 | 4 | 42735 | 0 | 32470787 |
Philadelphia chromosome negative | 22.54 | 12.34 | 4 | 42735 | 0 | 32470787 |
Anaphylactic reaction | 22.34 | 12.34 | 6 | 42733 | 30166 | 32440621 |
Aggression | 22.25 | 12.34 | 12 | 42727 | 39377 | 32431410 |
Large intestine infection | 22.21 | 12.34 | 17 | 42722 | 1423 | 32469364 |
Graft versus host disease in lung | 22.03 | 12.34 | 12 | 42727 | 558 | 32470229 |
Urticaria | 21.58 | 12.34 | 28 | 42711 | 59586 | 32411201 |
B-cell small lymphocytic lymphoma | 21.57 | 12.34 | 8 | 42731 | 147 | 32470640 |
Pancytopenia | 21.27 | 12.34 | 198 | 42541 | 91037 | 32379750 |
Arterial disorder | 21.26 | 12.34 | 16 | 42723 | 1306 | 32469481 |
Philadelphia positive chronic myeloid leukaemia | 21.24 | 12.34 | 7 | 42732 | 89 | 32470698 |
Ocular myasthenia | 21.19 | 12.34 | 9 | 42730 | 239 | 32470548 |
Dengue fever | 21.02 | 12.34 | 9 | 42730 | 244 | 32470543 |
Therapy partial responder | 20.94 | 12.34 | 29 | 42710 | 4901 | 32465886 |
Suicidal ideation | 20.94 | 12.34 | 12 | 42727 | 38071 | 32432716 |
Drug dependence | 20.89 | 12.34 | 3 | 42736 | 23481 | 32447306 |
Condition aggravated | 20.66 | 12.34 | 120 | 42619 | 155541 | 32315246 |
Rectosigmoid cancer | 20.40 | 12.34 | 8 | 42731 | 172 | 32470615 |
Neoplasm | 20.39 | 12.34 | 27 | 42712 | 4374 | 32466413 |
Complications of transplant surgery | 20.33 | 12.34 | 11 | 42728 | 505 | 32470282 |
Myelocyte count increased | 19.93 | 12.34 | 10 | 42729 | 392 | 32470395 |
Suicide attempt | 19.71 | 12.34 | 13 | 42726 | 38231 | 32432556 |
Transformation to acute myeloid leukaemia | 19.65 | 12.34 | 12 | 42727 | 694 | 32470093 |
Bone marrow oedema | 19.45 | 12.34 | 11 | 42728 | 551 | 32470236 |
Peripheral arterial occlusive disease | 19.08 | 12.34 | 30 | 42709 | 5679 | 32465108 |
Intentional product misuse | 18.92 | 12.34 | 12 | 42727 | 36039 | 32434748 |
Tachycardia | 18.90 | 12.34 | 48 | 42691 | 79040 | 32391747 |
Pericardial excision | 18.89 | 12.34 | 4 | 42735 | 6 | 32470781 |
Multiple-drug resistance | 18.80 | 12.34 | 24 | 42715 | 3751 | 32467036 |
Diaphragmatic disorder | 18.75 | 12.34 | 14 | 42725 | 1129 | 32469658 |
Cytopenia | 18.62 | 12.34 | 41 | 42698 | 10023 | 32460764 |
Mental status changes | 18.48 | 12.34 | 14 | 42725 | 38323 | 32432464 |
Wheezing | 18.38 | 12.34 | 13 | 42726 | 36861 | 32433926 |
Chest expansion decreased | 18.32 | 12.34 | 7 | 42732 | 140 | 32470647 |
Acoustic neuroma | 18.23 | 12.34 | 7 | 42732 | 142 | 32470645 |
Hyponatraemia | 17.98 | 12.34 | 45 | 42694 | 74468 | 32396319 |
Concomitant disease aggravated | 17.92 | 12.34 | 29 | 42710 | 5624 | 32465163 |
Lactic acidosis | 17.83 | 12.34 | 11 | 42728 | 33525 | 32437262 |
Leukaemia | 17.77 | 12.34 | 24 | 42715 | 3962 | 32466825 |
Asthma | 17.76 | 12.34 | 19 | 42720 | 44046 | 32426741 |
Medication error | 17.62 | 12.34 | 4 | 42735 | 22531 | 32448256 |
Platelet count increased | 17.61 | 12.34 | 38 | 42701 | 9163 | 32461624 |
Neuropathy peripheral | 17.43 | 12.34 | 48 | 42691 | 76934 | 32393853 |
Hepatic calcification | 17.41 | 12.34 | 9 | 42730 | 376 | 32470411 |
Acinetobacter sepsis | 17.36 | 12.34 | 5 | 42734 | 39 | 32470748 |
Marrow hyperplasia | 17.30 | 12.34 | 13 | 42726 | 1059 | 32469728 |
Therapy change | 17.28 | 12.34 | 20 | 42719 | 2825 | 32467962 |
Gelatinous transformation of the bone marrow | 17.27 | 12.34 | 4 | 42735 | 11 | 32470776 |
Vomiting | 17.21 | 12.34 | 418 | 42321 | 235139 | 32235648 |
Encephalopathy | 17.17 | 12.34 | 12 | 42727 | 34245 | 32436542 |
Atrial fibrillation | 17.11 | 12.34 | 87 | 42652 | 116617 | 32354170 |
Stress | 17.11 | 12.34 | 5 | 42734 | 23777 | 32447010 |
Myeloproliferative neoplasm | 17.04 | 12.34 | 10 | 42729 | 537 | 32470250 |
Adrenomegaly | 16.94 | 12.34 | 9 | 42730 | 398 | 32470389 |
Pseudomyxoma peritonei | 16.91 | 12.34 | 3 | 42736 | 0 | 32470787 |
Janus kinase 2 mutation | 16.91 | 12.34 | 3 | 42736 | 0 | 32470787 |
Hepatic embolisation | 16.91 | 12.34 | 3 | 42736 | 0 | 32470787 |
Cytoreductive surgery | 16.91 | 12.34 | 3 | 42736 | 0 | 32470787 |
Hydrocele operation | 16.91 | 12.34 | 3 | 42736 | 0 | 32470787 |
Drug reaction with eosinophilia and systemic symptoms | 16.79 | 12.34 | 11 | 42728 | 32474 | 32438313 |
Abscess drainage | 16.79 | 12.34 | 8 | 42731 | 280 | 32470507 |
Paternal exposure during pregnancy | 16.77 | 12.34 | 4 | 42735 | 13 | 32470774 |
Anaemia | 16.69 | 12.34 | 398 | 42341 | 223226 | 32247561 |
Costal cartilage fracture | 16.53 | 12.34 | 8 | 42731 | 290 | 32470497 |
Blood pressure decreased | 16.50 | 12.34 | 26 | 42713 | 51054 | 32419733 |
Coma | 16.49 | 12.34 | 19 | 42720 | 42593 | 32428194 |
Product dose omission issue | 16.48 | 12.34 | 74 | 42665 | 102501 | 32368286 |
Constipation | 16.46 | 12.34 | 98 | 42641 | 126275 | 32344512 |
Periorbital swelling | 16.35 | 12.34 | 8 | 42731 | 297 | 32470490 |
Essential thrombocythaemia | 16.26 | 12.34 | 5 | 42734 | 50 | 32470737 |
Biopsy bone marrow abnormal | 16.23 | 12.34 | 8 | 42731 | 302 | 32470485 |
Lung neoplasm malignant | 16.19 | 12.34 | 52 | 42687 | 15911 | 32454876 |
Intentional product use issue | 16.14 | 12.34 | 19 | 42720 | 42192 | 32428595 |
Pigmentation disorder | 15.93 | 12.34 | 17 | 42722 | 2195 | 32468592 |
Cellulitis | 15.82 | 12.34 | 26 | 42713 | 50204 | 32420583 |
Insomnia | 15.76 | 12.34 | 73 | 42666 | 100275 | 32370512 |
Growth failure | 15.67 | 12.34 | 5 | 42734 | 57 | 32470730 |
Colitis | 15.61 | 12.34 | 13 | 42726 | 33938 | 32436849 |
Trisomy 8 | 15.36 | 12.34 | 5 | 42734 | 61 | 32470726 |
Lactose intolerance | 15.11 | 12.34 | 13 | 42726 | 1285 | 32469502 |
Thrombosis | 15.05 | 12.34 | 23 | 42716 | 45731 | 32425056 |
Intestinal congestion | 14.94 | 12.34 | 4 | 42735 | 23 | 32470764 |
Bladder cancer | 14.87 | 12.34 | 38 | 42701 | 10218 | 32460569 |
Metastases to bladder | 14.86 | 12.34 | 5 | 42734 | 68 | 32470719 |
Bence Jones proteinuria | 14.83 | 12.34 | 3 | 42736 | 3 | 32470784 |
Metastases to heart | 14.58 | 12.34 | 6 | 42733 | 147 | 32470640 |
Hypereosinophilic syndrome | 14.53 | 12.34 | 7 | 42732 | 251 | 32470536 |
Parakeratosis | 14.46 | 12.34 | 6 | 42733 | 150 | 32470637 |
Product prescribing error | 14.45 | 12.34 | 4 | 42735 | 19713 | 32451074 |
Angioedema | 14.24 | 12.34 | 16 | 42723 | 36273 | 32434514 |
Disease recurrence | 14.23 | 12.34 | 50 | 42689 | 16014 | 32454773 |
Lacrimation increased | 14.14 | 12.34 | 31 | 42708 | 7553 | 32463234 |
Hyperchromic anaemia | 14.14 | 12.34 | 4 | 42735 | 29 | 32470758 |
Product use in unapproved indication | 14.14 | 12.34 | 176 | 42563 | 87028 | 32383759 |
Unevaluable event | 14.08 | 12.34 | 14 | 42725 | 33572 | 32437215 |
Loss of personal independence in daily activities | 13.99 | 12.34 | 9 | 42730 | 26824 | 32443963 |
Aspiration bone marrow | 13.62 | 12.34 | 3 | 42736 | 6 | 32470781 |
Clear cell sarcoma of soft tissue | 13.62 | 12.34 | 3 | 42736 | 6 | 32470781 |
Gastric neoplasm | 13.47 | 12.34 | 5 | 42734 | 92 | 32470695 |
Leukostasis syndrome | 13.38 | 12.34 | 4 | 42735 | 36 | 32470751 |
Therapy responder | 13.32 | 12.34 | 6 | 42733 | 184 | 32470603 |
Metastasis | 13.32 | 12.34 | 20 | 42719 | 3637 | 32467150 |
Pneumonia aspiration | 13.24 | 12.34 | 21 | 42718 | 41135 | 32429652 |
Oropharyngeal pain | 13.22 | 12.34 | 13 | 42726 | 31339 | 32439448 |
Ejection fraction decreased | 13.16 | 12.34 | 52 | 42687 | 17606 | 32453181 |
Bladder neoplasm surgery | 13.09 | 12.34 | 4 | 42735 | 39 | 32470748 |
Blast cell proliferation | 13.02 | 12.34 | 3 | 42736 | 8 | 32470779 |
Transitional cell carcinoma | 13.00 | 12.34 | 15 | 42724 | 2112 | 32468675 |
Hypoglycaemia | 12.99 | 12.34 | 33 | 42706 | 54349 | 32416438 |
Cancer surgery | 12.88 | 12.34 | 8 | 42731 | 477 | 32470310 |
Hypertension | 12.85 | 12.34 | 111 | 42628 | 131639 | 32339148 |
Orthostatic hypotension | 12.84 | 12.34 | 9 | 42730 | 25641 | 32445146 |
Bone development abnormal | 12.83 | 12.34 | 4 | 42735 | 42 | 32470745 |
Ventricular tachycardia | 12.75 | 12.34 | 9 | 42730 | 25547 | 32445240 |
Chills | 12.74 | 12.34 | 56 | 42683 | 78028 | 32392759 |
Musculoskeletal stiffness | 12.66 | 12.34 | 20 | 42719 | 39244 | 32431543 |
Drug-induced liver injury | 12.64 | 12.34 | 8 | 42731 | 24055 | 32446732 |
Laryngeal cancer stage III | 12.52 | 12.34 | 3 | 42736 | 10 | 32470777 |
Breast oedema | 12.52 | 12.34 | 3 | 42736 | 10 | 32470777 |
Hyperkeratosis | 12.51 | 12.34 | 19 | 42720 | 3490 | 32467297 |
Erythropoiesis abnormal | 12.48 | 12.34 | 6 | 42733 | 214 | 32470573 |
Conjunctival haemorrhage | 12.44 | 12.34 | 17 | 42722 | 2838 | 32467949 |
Heart rate decreased | 12.41 | 12.34 | 9 | 42730 | 25191 | 32445596 |
Skin neoplasm excision | 12.35 | 12.34 | 7 | 42732 | 352 | 32470435 |
Source | Code | Description |
---|---|---|
ATC | L01EA01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS BCR-ABL tyrosine kinase inhibitors |
FDA MoA | N0000020009 | Bcr-Abl Tyrosine Kinase Inhibitors |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D047428 | Protein Kinase Inhibitors |
FDA EPC | N0000175605 | Kinase Inhibitor |
FDA MoA | N0000182137 | Cytochrome P450 2D6 Inhibitors |
FDA MoA | N0000182141 | Cytochrome P450 3A4 Inhibitors |
CHEBI has role | CHEBI:35610 | cytostatic |
CHEBI has role | CHEBI:38637 | protein tyrosine kinase inhibitor |
CHEBI has role | CHEBI:68495 | Type I programmed cell-death inducer |
CHEBI has role | CHEBI:149553 | anti-coronaviral agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Dermatofibrosarcoma protuberans | indication | 276799004 | |
Systemic mast cell disease | indication | 397016004 | DOID:349 |
Blastic phase chronic myeloid leukemia | indication | 413656006 | |
Chronic eosinophilic leukemia | indication | 413836008 | |
Chronic phase chronic myeloid leukemia | indication | 413847001 | |
Gastrointestinal stromal tumor | indication | 420120006 | DOID:9253 |
Idiopathic hypereosinophilic syndrome | indication | 423294001 | |
Philadelphia chromosome-positive acute lymphoblastic leukemia | indication | 425688002 | |
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia | indication | 449108003 | |
Myelodysplastic/myeloproliferative diseases with re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR) | indication | 738527001 | |
Chronic Myelocytic Leukemia Accelerated Phase | indication | ||
Heart valve disorder | contraindication | 368009 | DOID:4079 |
Cerebral edema | contraindication | 2032001 | |
Hypophosphatemia | contraindication | 4996001 | |
Congenital heart disease | contraindication | 13213009 | |
Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
Pulmonary edema | contraindication | 19242006 | DOID:11396 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Body fluid retention | contraindication | 43498006 | |
Chronic heart failure | contraindication | 48447003 | |
Myocarditis | contraindication | 50920009 | DOID:820 |
Gastrointestinal perforation | contraindication | 51875005 | |
Hepatic failure | contraindication | 59927004 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Gastrointestinal hemorrhage | contraindication | 74474003 | |
Left heart failure | contraindication | 85232009 | |
Cardiogenic shock | contraindication | 89138009 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Bleeding | contraindication | 131148009 | |
Liver function tests abnormal | contraindication | 166603001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Edema | contraindication | 267038008 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Pericardial effusion | contraindication | 373945007 | DOID:118 |
Purpuric disorder | contraindication | 387778001 | |
Ascites | contraindication | 389026000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Disorder of coronary artery | contraindication | 414024009 | |
Obesity | contraindication | 414916001 | DOID:9970 |
Pleural Effusions | contraindication | ||
Chronic Heart Failure Following Myocardial Infarction | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.96 | acidic |
pKa2 | 8.49 | Basic |
pKa3 | 4.34 | Basic |
pKa4 | 3.73 | Basic |
pKa5 | 2.2 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Mast/stem cell growth factor receptor Kit | Kinase | INHIBITOR | Kd | 7.89 | CHEMBL | CHEMBL | |||
Platelet-derived growth factor receptor beta | Kinase | INHIBITOR | Kd | 7.85 | CHEMBL | CHEMBL | |||
Tyrosine-protein kinase ABL1 | Kinase | INHIBITOR | Kd | 8.96 | CHEMBL | CHEMBL | |||
Histamine H2 receptor | GPCR | Ki | 5.71 | DRUG MATRIX | |||||
Carbonic anhydrase 2 | Enzyme | Ki | 7.52 | CHEMBL | |||||
Multidrug resistance-associated protein 1 | Transporter | WOMBAT-PK | |||||||
ATP-binding cassette sub-family G member 2 | Transporter | IC50 | 5.47 | CHEMBL | |||||
Carbonic anhydrase 1 | Enzyme | Ki | 7.50 | CHEMBL | |||||
Carbonic anhydrase 4 | Enzyme | Ki | 5.34 | CHEMBL | |||||
Ribosyldihydronicotinamide dehydrogenase [quinone] | Enzyme | IC50 | 6.40 | CHEMBL | |||||
Carbonic anhydrase 9 | Enzyme | Ki | 7.12 | CHEMBL | |||||
Carbonic anhydrase 12 | Enzyme | Ki | 6.01 | CHEMBL | |||||
Epidermal growth factor receptor | Kinase | Kd | 5.12 | CHEMBL | |||||
Carbonic anhydrase 5A, mitochondrial | Enzyme | Ki | 4.69 | CHEMBL | |||||
Carbonic anhydrase 5B, mitochondrial | Enzyme | Ki | 4.77 | CHEMBL | |||||
Carbonic anhydrase 7 | Enzyme | Ki | 6.96 | CHEMBL | |||||
Proto-oncogene tyrosine-protein kinase Src | Kinase | Ki | 4.51 | CHEMBL | |||||
Tyrosine-protein kinase Lck | Kinase | Kd | 7.40 | CHEMBL | |||||
Tyrosine-protein kinase Fyn | Kinase | Kd | 5.51 | CHEMBL | |||||
RAF proto-oncogene serine/threonine-protein kinase | Kinase | Kd | 5.77 | CHEMBL | |||||
Serine/threonine-protein kinase B-raf | Kinase | Kd | 5.48 | CHEMBL | |||||
Receptor-type tyrosine-protein kinase FLT3 | Kinase | Kd | 5.20 | CHEMBL | |||||
Vascular endothelial growth factor receptor 2 | Kinase | IC50 | 4.59 | CHEMBL | |||||
Macrophage colony-stimulating factor 1 receptor | Kinase | Kd | 7.96 | CHEMBL | |||||
Platelet-derived growth factor receptor alpha | Kinase | Kd | 7.51 | CHEMBL | |||||
Insulin receptor | Kinase | AGONIST | Ki | 5 | PDSP | ||||
Thromboxane-A synthase | Enzyme | IC50 | 6.70 | DRUG MATRIX | |||||
Mitogen-activated protein kinase 8 | Kinase | Kd | 5.49 | CHEMBL | |||||
Carbonic anhydrase 3 | Enzyme | Ki | 6.28 | CHEMBL | |||||
Carbonic anhydrase 6 | Enzyme | Ki | 6.41 | CHEMBL | |||||
Mitogen-activated protein kinase 10 | Kinase | Kd | 5.51 | CHEMBL | |||||
Tyrosine-protein kinase JAK2 | Kinase | Ki | 5 | PDSP | |||||
Tyrosine-protein kinase SYK | Kinase | IC50 | 5.30 | CHEMBL | |||||
Ephrin type-A receptor 8 | Kinase | Kd | 5.85 | CHEMBL | |||||
Tyrosine-protein kinase Lyn | Kinase | Kd | 6.05 | CHEMBL | |||||
Cytoplasmic tyrosine-protein kinase BMX | Kinase | Ki | 5 | PDSP | |||||
Carbonic anhydrase 14 | Enzyme | Ki | 6.33 | CHEMBL | |||||
Fibroblast growth factor receptor 1 | Kinase | Ki | 5 | PDSP | |||||
Serine/threonine-protein kinase PLK4 | Kinase | Kd | 5.11 | CHEMBL | |||||
Abelson tyrosine-protein kinase 2 | Kinase | Kd | 8.22 | CHEMBL | |||||
Fibroblast growth factor receptor 2 | Kinase | Ki | 5 | PDSP | |||||
Serine/threonine-protein kinase 17A | Kinase | Kd | 5.55 | CHEMBL | |||||
Tyrosine-protein kinase Fgr | Kinase | Kd | 5.62 | CHEMBL | |||||
Mitogen-activated protein kinase 14 | Kinase | IC50 | 4.86 | CHEMBL | |||||
Tyrosine-protein kinase FRK | Kinase | Kd | 5.82 | CHEMBL | |||||
Dual specificity protein kinase CLK1 | Kinase | Kd | 5.35 | CHEMBL | |||||
Cyclin-G-associated kinase | Kinase | Kd | 6 | CHEMBL | |||||
Ephrin type-B receptor 1 | Kinase | Ki | 5 | PDSP | |||||
Dual specificity protein kinase CLK4 | Kinase | Kd | 5.68 | CHEMBL | |||||
Mitogen-activated protein kinase 9 | Kinase | Kd | 5.28 | CHEMBL | |||||
Epithelial discoidin domain-containing receptor 1 | Kinase | Kd | 9.15 | CHEMBL | |||||
Ephrin type-B receptor 4 | Kinase | Ki | 5 | PDSP | |||||
Lysine--tRNA ligase | Enzyme | Ki | 5.30 | CHEMBL | |||||
Non-receptor tyrosine-protein kinase TYK2 | Kinase | Kd | 5.06 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase MLT | Kinase | Kd | 5.59 | CHEMBL | |||||
Casein kinase II subunit alpha' | Kinase | Kd | 5.42 | CHEMBL | |||||
Maternal embryonic leucine zipper kinase | Kinase | Kd | 5.72 | CHEMBL | |||||
Serine/threonine-protein kinase TNNI3K | Kinase | Kd | 5.37 | CHEMBL | |||||
Discoidin domain-containing receptor 2 | Kinase | Kd | 7.82 | CHEMBL | |||||
Tyrosine-protein kinase Blk | Kinase | Kd | 6.28 | CHEMBL | |||||
Cyclin-dependent kinase 19 | Kinase | Kd | 5.26 | CHEMBL | |||||
Homeodomain-interacting protein kinase 4 | Kinase | Kd | 6.02 | CHEMBL | |||||
Interleukin-1 receptor-associated kinase 1 | Kinase | Kd | 5.92 | CHEMBL | |||||
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma | Kinase | Kd | 6.42 | CHEMBL | |||||
Solute carrier family 22 member 2 | Transporter | IC50 | 5.38 | CHEMBL | |||||
Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 7.40 | CHEMBL | |||||
Multidrug and toxin extrusion protein 2 | Transporter | IC50 | 6.46 | CHEMBL | |||||
Solute carrier family 22 member 3 | Transporter | IC50 | 4.59 | CHEMBL | |||||
Platelet-derived growth factor receptor | Kinase | IC50 | 7.30 | CHEMBL | |||||
Tyrosine-protein kinase ABL | Kinase | IC50 | 7.40 | CHEMBL | |||||
Bcr/Abl fusion protein | Kinase | Ki | 7.85 | CHEMBL | |||||
Multidrug resistance protein 1 | Transporter | IC50 | 5.14 | CHEMBL | |||||
ATP-dependent RNA helicase DDX3X | Enzyme | Kd | 6.36 | CHEMBL | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 6.13 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.27 | DRUG MATRIX | |||||
Carbonic anhydrase 13 | Enzyme | Ki | 5.13 | CHEMBL | |||||
Carbonic anhydrase 15 | Enzyme | Ki | 7.11 | CHEMBL | |||||
Proto-oncogene tyrosine-protein kinase Src | Kinase | IC50 | 5.56 | CHEMBL | |||||
Tyrosine-protein kinase ABL1 | Kinase | IC50 | 7.97 | CHEMBL | |||||
Platelet-derived growth factor receptor beta | Kinase | IC50 | 6.79 | CHEMBL |
ID | Source |
---|---|
4021257 | VUID |
N0000148698 | NUI |
D01441 | KEGG_DRUG |
220127-57-1 | SECONDARY_CAS_RN |
4021257 | VANDF |
4021258 | VANDF |
C0939537 | UMLSCUI |
CHEBI:45783 | CHEBI |
STI | PDB_CHEM_ID |
CHEMBL941 | ChEMBL_ID |
CHEMBL1642 | ChEMBL_ID |
D000068877 | MESH_DESCRIPTOR_UI |
DB00619 | DRUGBANK_ID |
5687 | IUPHAR_LIGAND_ID |
8031 | INN_ID |
BKJ8M8G5HI | UNII |
5291 | PUBCHEM_CID |
282386 | RXNORM |
16030 | MMSL |
238904 | MMSL |
41395 | MMSL |
d04758 | MMSL |
009151 | NDDF |
009152 | NDDF |
129558005 | SNOMEDCT_US |
391634008 | SNOMEDCT_US |
414460008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0248 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0249 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 26 sections |
Gleevec | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0401 | TABLET | 100 mg | ORAL | NDA | 32 sections |
Gleevec | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0649 | TABLET | 400 mg | ORAL | NDA | 32 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7629 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 28 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7630 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 28 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-2245 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 28 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-2246 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 28 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6621 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 26 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6901 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
imatinib mesylate | Human Prescription Drug Label | 1 | 16714-704 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 29 sections |
imatinib mesylate | Human Prescription Drug Label | 1 | 16714-705 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 29 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42292-043 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 28 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42292-044 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 28 sections |
Imatinib | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-344 | TABLET | 100 mg | ORAL | ANDA | 26 sections |
Imatinib | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-345 | TABLET | 400 mg | ORAL | ANDA | 26 sections |
imatinib mesylate | Human Prescription Drug Label | 1 | 47335-472 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 28 sections |
imatinib mesylate | Human Prescription Drug Label | 1 | 47335-475 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 28 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-426 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-427 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 26 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-269 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 28 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-270 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 28 sections |
IMATINIB MESYLATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51991-376 | TABLET, COATED | 100 mg | ORAL | ANDA | 33 sections |
IMATINIB MESYLATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51991-377 | TABLET, COATED | 400 mg | ORAL | ANDA | 33 sections |
Imatinib Mesylate | Human Prescription Drug Label | 1 | 59651-240 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 28 sections |
Imatinib Mesylate | Human Prescription Drug Label | 1 | 59651-241 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 28 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59923-723 | TABLET, COATED | 100 mg | ORAL | ANDA | 32 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59923-724 | TABLET, COATED | 400 mg | ORAL | ANDA | 32 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-2900 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
Imatinib Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-2901 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 26 sections |